Xavier Thomas is in charge of the management and treatment of adult patients with acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) in the Department of Hematology at the Lyon-Sud Hospital (France). He is member of the American Society of Hematology (ASH), American Society of Clinical Oncology (ASCO), American Association for Cancer Research (AACR) and European Hematology Association (EHA). He is actively involved in the Group for Research in Adult Acute Lymphoblastic Leukemia (GRAALL) and the Acute Leukemia French Association (ALFA). He has published more than 400 peer-reviewed papers and has served as a referee for several journals, including Blood, Leukemia, The Lancet, The New England Journal of Medicine, Leukemia & Lymphoma, and Cancer.
Browse specialties
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs
ctDNA and bladder cancer: Current understanding and beyond
ROS1 fusion-positive NSCLC
NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC
Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy
ALK fusion-positive NSCLC: International approaches to management
RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC
COVID-19 & cancer
Conferences